<DOC>
	<DOCNO>NCT00477152</DOCNO>
	<brief_summary>The aim study evaluate safety , effectiveness ease use subcutaneous ( SC ) rehydration use HYLENEX-augmented SC infusion fluid electrolytes rehydration pediatric patient mild moderate dehydration .</brief_summary>
	<brief_title>Study Subcutaneous Rehydration With Recombinant Human Hyaluronidase Infants Children</brief_title>
	<detailed_description>Pediatric patient ( 2 month 10 year age ) , present emergency department ( ED ) mild moderate dehydration require parenteral rehydration , treat HYLENEX-augmented subcutaneous ( SC ) rehydration . An initial volume 20 mL/kg isotonic fluid administer continuous SC infusion first hour , additional SC rehydration could continue clinically indicate . The preferred anatomic site SC infusion anterior thigh , unless override preference alternate site . The duration HYLENEX-augmented SC rehydration minimum 1 hour maximum 72 hour . The investigator designee perform clinical assessment subject 's hydration status baseline end SC infusion discharge ED . Other assessment effectiveness safety make directly rehydration period ED stay , telephone Days 3 7 discharge ED .</detailed_description>
	<mesh_term>Dehydration</mesh_term>
	<criteria>Child , 2 month 10 year age Body weight less 42 kg Presenting emergency department mild moderate dehydration ( Gorelick dehydration classification : presence 1 6 [ possible 10 ] moderate severe sign symptom ) require parenteral rehydration In shock lifethreatening situation ( dehydration ) Severe dehydration Requires intravenous ( IV ) therapy another indication Indwelling IV catheter ( except one intend strictly clinical laboratory sample collection ) Already receive rehydration therapy IV within prior 48 hour substantial oral fluid immediately enrollment Condition preclude subcutaneous injection infusion site evaluation anterior thigh elect infusion site Reason hospital admission extend emergency department stay dehydration Known hypersensitivity hyaluronidase another ingredient HYLENEX Hyponatremia hypernatremia Hypokalemia Medical condition likely interfere ability fully complete study protocolspecified assessment Medical history , screen examination find historical clinical laboratory result preclude safe participation study might adversely effect interpretation study result Participated study investigational drug device within 30 day prior study</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>dehydration</keyword>
	<keyword>fluid therapy</keyword>
	<keyword>pediatrics</keyword>
	<keyword>emergency medicine</keyword>
	<keyword>hyaluronoglucosaminidase</keyword>
	<keyword>hyaluronidase</keyword>
	<keyword>hypodermoclysis</keyword>
	<keyword>clysis</keyword>
	<keyword>subcutaneous hydration</keyword>
	<keyword>subcutaneous rehydration</keyword>
	<keyword>hyaluronan</keyword>
	<keyword>rHuPH20</keyword>
</DOC>